Immunic (NASDAQ:IMUX) announced positive results from the part C portion of its Phase 1 clinical trial of IMU-856 in patients with celiac disease. The company believes that this data set provides initial clinical proof...
Search results for - IMUX
SVB Leerink starts Immunic at OP, PT $45
SVB Leerink launched coverage of Immunic (NASDAQ:IMUX) with an “outperform” rating and $45 price target. The stock closed at $18.87 on Oct. 1. Immunic is focused on development of novel therapeutics for the treatment of...
Immunic reports first patients enrolled in Phase 2 COVID-19 trial
The first patients have been enrolled in an investigator-sponsored Phase 2 study evaluating Immunic Therapeutics‘ (NASDAQ:IMUX) IMU-838 for the treatment of COVID-19. IMU-838 is a selective immune modulator that...
Roth starts Immunic at buy; PT $44
Roth Capital Partners launched coverage of Immunic (NASDAQ:IMUX) with a “buy” rating and $44 price target. The stock closed at $5.74 on March 24. Immunic is focused on developing innovative new modulators of the immune...
Immunic completes enrollment for Phase 2 MS trial
Immunic (NASDAQ:IMUX) completed enrollment for its Phase 2 trial assessing IMU-838 for the treatment of relapsing-remitting multiple sclerosis (RRMS). IMU-838 is a selective immune modulator that blocks the enzyme...
Ladenburg starts Immunic at buy; PT $50
Ladenburg Thalmann initiated coverage of Immunic (NASDAQ:IMUX) with a “buy” rating and $50 price target. The stock closed at $14.30 on April 22.
